mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Teachey, David T., Sheen, Cecilia, Hall, Junior, Ryan, Theresa, Brown, Valerie I., Fish, Jonathan, Reid, Gregor S. D., Seif, Alix E., Norris, Robin, Chang, Yueh J., Carroll, Martin, Grupp, Stephan A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2008
Soggetti:
Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/
https://ncbi.nlm.nih.gov/pubmed/18544682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi